Further studies focusing on Akt2 signaling in CD8+ T-cell differentiation could uncover additional mechanisms that enhance T-cell persistence, memory potential, and antitumor efficacy, thereby broadening its therapeutic applicability in cancer immunotherapy. The gene discussed is AKT2; the disease is cancer.